Japan · Delayed Price · Currency is JPY Fuji Pharma Statistics
Total Valuation
Fuji Pharma has a market cap or net worth of JPY 46.24 billion. The enterprise value is 69.94 billion.
| Market Cap | 46.24B |
| Enterprise Value | 69.94B |
Important Dates
The next estimated earnings date is Thursday, February 5, 2026.
| Earnings Date | Feb 5, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
Fuji Pharma has 24.46 million shares outstanding. The number of shares has increased by 0.38% in one year.
| Current Share Class | 24.46M |
| Shares Outstanding | 24.46M |
| Shares Change (YoY) | +0.38% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 41.40% |
| Owned by Institutions (%) | 13.97% |
| Float | 11.66M |
Valuation Ratios
The trailing PE ratio is 15.38 and the forward PE ratio is 12.42.
| PE Ratio | 15.38 |
| Forward PE | 12.42 |
| PS Ratio | 0.89 |
| PB Ratio | 0.99 |
| P/TBV Ratio | 1.40 |
| P/FCF Ratio | 12.11 |
| P/OCF Ratio | 7.97 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.81, with an EV/FCF ratio of 18.31.
| EV / Earnings | 23.31 |
| EV / Sales | 1.35 |
| EV / EBITDA | 7.81 |
| EV / EBIT | 14.02 |
| EV / FCF | 18.31 |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.66.
| Current Ratio | 1.55 |
| Quick Ratio | 0.82 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 3.45 |
| Debt / FCF | 8.10 |
| Interest Coverage | 15.12 |
Financial Efficiency
Return on equity (ROE) is 6.49% and return on invested capital (ROIC) is 4.09%.
| Return on Equity (ROE) | 6.49% |
| Return on Assets (ROA) | 3.40% |
| Return on Invested Capital (ROIC) | 4.09% |
| Return on Capital Employed (ROCE) | 7.99% |
| Revenue Per Employee | 29.36M |
| Profits Per Employee | 1.70M |
| Employee Count | 1,760 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 1.58 |
Taxes
In the past 12 months, Fuji Pharma has paid 1.00 billion in taxes.
| Income Tax | 1.00B |
| Effective Tax Rate | 25.00% |
Stock Price Statistics
The stock price has increased by +24.24% in the last 52 weeks. The beta is 0.29, so Fuji Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | +24.24% |
| 50-Day Moving Average | 1,790.16 |
| 200-Day Moving Average | 1,508.09 |
| Relative Strength Index (RSI) | 57.07 |
| Average Volume (20 Days) | 79,760 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Fuji Pharma had revenue of JPY 51.68 billion and earned 3.00 billion in profits. Earnings per share was 122.93.
| Revenue | 51.68B |
| Gross Profit | 20.76B |
| Operating Income | 4.99B |
| Pretax Income | 4.00B |
| Net Income | 3.00B |
| EBITDA | 8.96B |
| EBIT | 4.99B |
| Earnings Per Share (EPS) | 122.93 |
Balance Sheet
The company has 7.25 billion in cash and 30.94 billion in debt, with a net cash position of -23.69 billion or -968.79 per share.
| Cash & Cash Equivalents | 7.25B |
| Total Debt | 30.94B |
| Net Cash | -23.69B |
| Net Cash Per Share | -968.79 |
| Equity (Book Value) | 46.91B |
| Book Value Per Share | 1,917.91 |
| Working Capital | 16.93B |
Cash Flow
In the last 12 months, operating cash flow was 5.80 billion and capital expenditures -1.98 billion, giving a free cash flow of 3.82 billion.
| Operating Cash Flow | 5.80B |
| Capital Expenditures | -1.98B |
| Free Cash Flow | 3.82B |
| FCF Per Share | 156.20 |
Margins
Gross margin is 40.18%, with operating and profit margins of 9.66% and 5.81%.
| Gross Margin | 40.18% |
| Operating Margin | 9.66% |
| Pretax Margin | 7.74% |
| Profit Margin | 5.81% |
| EBITDA Margin | 17.33% |
| EBIT Margin | 9.66% |
| FCF Margin | 7.39% |
Dividends & Yields
This stock pays an annual dividend of 47.00, which amounts to a dividend yield of 2.47%.
| Dividend Per Share | 47.00 |
| Dividend Yield | 2.47% |
| Dividend Growth (YoY) | 9.41% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 34.53% |
| Buyback Yield | -0.38% |
| Shareholder Yield | 2.10% |
| Earnings Yield | 6.49% |
| FCF Yield | 8.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 27, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Jun 27, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Fuji Pharma has an Altman Z-Score of 1.93 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.93 |
| Piotroski F-Score | 7 |